General Information of This Linker
Linker ID
LIN0TPKXU
Linker Name
Mc-Ala-Ala-Ala
Antibody-Linker Relation
Cleavable
Structure
Formula
C19H28N4O7
Isosmiles
C[C@H](NC(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)O
InChI
InChI=1S/C19H28N4O7/c1-11(17(27)21-12(2)18(28)22-13(3)19(29)30)20-14(24)7-5-4-6-10-23-15(25)8-9-16(23)26/h8-9,11-13H,4-7,10H2,1-3H3,(H,20,24)(H,21,27)(H,22,28)(H,29,30)/t11-,12+,13-/m0/s1
InChIKey
UCOOONSXCROXON-XQQFMLRXSA-N
Pharmaceutical Properties
Molecule Weight
424.454
Polar area
161.98
Complexity
424.1957992
xlogp Value
-0.9295
Heavy Count
30
Rot Bonds
12
Hbond acc
6
Hbond Donor
4
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
IMGC-936 [Phase 1/2]
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04622774  Clinical Status Phase 1
Clinical Description
A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.
Primary Endpoint
During dose escalation measure incidence and severity of Treatment Emergent Adverse Events, During dose escalation characterize dose-limiting toxicities (DLTs), During expansion describe the overall response rate.
Other Endpoint
During dose escalation and expansion to characterize study drug concentration and the concentration of anti-drug antibody, During dose expansion describe the duration of response and progression free survival, During dose escalation to describe the objective response rate and duration of response, During dose expansion measure incidence and severity of Treatment Emergent Adverse Events.

   Click to Show/Hide
References
Ref 1 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors, NCT04622774